Individual genotype influences effectiveness of HIV vaccine

August 8, 2014, Journal of Clinical Investigation

Almost 40 million people worldwide live with HIV/AIDS. Despite great effort, HIV-1 vaccine development has been challenging. A recent HIV vaccine trial, known as RV144, revealed that a combination of 2 vaccines protected some individuals from HIV infection. Individuals in the trial that made antibodies that bound to a specific region of the HIV envelope protein had a decreased risk of HIV infection.

A new study in the Journal of Clinical Investigation reveals that an individual's genotype correlates with their ability to develop immunity to HIV in response to vaccination. Sue Li and colleagues at the Fred Hutchinson Cancer Research Center sequenced genes in RV144 participants that are involved in . The authors identified single nucleotide variations in genes that encode antibody receptors, which are important for .

They found that the majority of individuals with specific variants of the FCGR2C gene were protected from HIV infection after vaccination whereas a different form of FCGR2C was not associated with protection.

Their study provides important insight into the variable response of individuals in the RV144 trial.

Explore further: Past HIV vaccine trials reveal new path to success

More information: FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial, J Clin Invest. DOI: 10.1172/JCI75539

Related Stories

Past HIV vaccine trials reveal new path to success

March 19, 2014
A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine.

Mechanism found for development of protective HIV antibodies

July 24, 2014
Scientists at Duke Medicine have found an immunologic mechanism that makes broadly neutralizing antibodies in people who are HIV-1 infected.

Research may be beating HIV, but a vaccine remains distant

July 11, 2014
Three decades since the onset of the infection in a global population, HIV care and treatment is looking very different. Given the difficulties involved, it is remarkable that having developed good treatments, the global ...

Possible clues found to why HIV vaccine showed modest protection

April 4, 2012
Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who ...

Durable end to AIDS will require HIV vaccine development

February 5, 2014
Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately ...

Antibodies help protect monkeys from HIV-like virus, scientists show

May 5, 2011
Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.